Endonovo Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Endonovo Therapeutics, Inc. scores 2/10 on the AskCyborg Cyborg Score (Challenged). Pre-revenue microcap biotech with unique electroceutical technology but severely constrained resources and execution capacity. The company has a market capitalization of $110K with trailing twelve-month revenue of $16K. The company has 1 employee and shows minimal commercial traction despite having novel technology platforms.
What is Endonovo Therapeutics, Inc.'s industry? Endonovo Therapeutics, Inc. (endonovo.com) operates in Regenerative Medicine. AskCyborg classifies Endonovo Therapeutics, Inc. under Regenerative Medicine in its company registry.
Endonovo Therapeutics is a biotechnology company engaged in the development, manufacture, and distribution of non-invasive Electroceutical medical devices for regenerative medicine. The company's Immunotronics platfor...
Cyborg Score thesis
Pre-revenue microcap biotech with unique electroceutical technology but severely constrained resources and execution...
Read the full analyst-debate transcript →Get the Latest Endonovo Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeEndonovo Therapeutics, Inc. Overview
Pro stress-test →Endonovo Therapeutics is a biotechnology company engaged in the development, manufacture, and distribution of non-invasive Electroceutical medical devices for regenerative medicine. The company's Immunotronics platform is a non-invasive bioelectronic device for treating vital organ failure through reduction of inflammation, while Cytotronics uses Time-Varying Electromagnetic Fields for tissue engineering and cell therapies.
Strategic Profile
Pro stress-test →Endonovo is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The company's primary product offering is SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. The company operates as a microcap biotech with extremely limited resources and liquidity.
Competitive Landscape
Pro stress-test →Endonovo operates in the bioelectronic regenerative medicine space, competing indirectly with broader regenerative medicine companies and electroceutical device developers. The company faces significant competitive disadvantages due to its minimal capitalization, staffing constraints, and lack of clinical validation relative to better-funded biotech players in wound care, tissue engineering, and organ regeneration.
Industry Context
Endonovo Therapeutics, Inc. operates in Regenerative Medicine.
Key facts
Headquarters: Woodland Hills, US · Employees: 1 · Revenue: $16K (trailing twelve months) · Market cap: $31K-$181K (as of June 2026)